Blog
RSS FeedPosted by Michael Wonder on 26 Mar 2018
ICER to assess therapies for hereditary angioedema in upcoming assessment
23 March 2018 - Review will be subject of October CTAF meeting; open input now being accepted until 9 April. ...
Posted by Michael Wonder on 24 Mar 2018
ICER final report on CAR-T therapies highlights need for systemwide changes to ensure affordability and access to innovative, one-time therapies
23 March 2018 - Policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...
Posted by Michael Wonder on 16 Mar 2018
ICER releases draft evidence report on CFTR modulator therapies for cystic fibrosis
15 March 2018 - Public comment period now open until 12 April; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018. ...
Posted by Michael Wonder on 13 Mar 2018
America’s “NICE”?
12 March 2018 - “The health of a democratic society may be measured by the quality of functions performed by ...
Posted by Michael Wonder on 13 Mar 2018
ICER requests public comment on two draft scoping documents: treatments for high-risk prostate cancer and amyloidosis
12 March 2018 - The ICER has posted two draft scoping documents outlining planned reviews of 1) three anti-androgen therapies ...
Posted by Michael Wonder on 12 Mar 2018
Regeneron and Sanofi announce plans to make Praluent (alirocumab) more accessible and affordable for patients with the greatest health risk and unmet need
10 March 2018 - For payers willing to reduce access barriers for high-risk patients, companies will offer net price within a ...
Posted by Michael Wonder on 11 Mar 2018
Institute for Clinical and Economic Review updates value-based price benchmark for alirocumab, a PCSK9 inhibitor for treatment of high cholesterol
10 March 2018 - Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, ...
Posted by Michael Wonder on 11 Mar 2018
Is ICER NICEr?
21 February 2018 - Similar to NICE in the UK and the PBAC in Australia, the Institute for Clinical and Economic ...
Posted by Michael Wonder on 22 Feb 2018
A health economics approach to US value frameworks: serving the needs of decision-making
22 February 2018 - Value assessment is an integral component of decision making in health and is the focus of a ...
Posted by Michael Wonder on 20 Feb 2018
Does the USA need a national health technology assessor?
19 February 2018 - In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant ...
Posted by Michael Wonder on 18 Feb 2018
ICER report finds costs of approved CAR-T therapies align with clinical benefit
15 February 2018 - Report will be subject to public deliberation during CTAF meeting on 2 March 2018. ...
Posted by Michael Wonder on 16 Feb 2018
ICER to assess treatments for amyloidosis, prostate cancer in upcoming reports
16 February 2018 - Both reports will be subject of September Midwest CEPAC meeting; open Input now being accepted until 7 ...
Posted by Michael Wonder on 14 Feb 2018
ICER final report: broader benefits of voretigene neparvovec to affected individuals and society provide reasonable long-term value despite high price
14 February 2018 - Appraisal committee vote reveals differences in judgments on value given pricing far above traditional cost-effectiveness levels. ...